Skip to main content
. Author manuscript; available in PMC: 2019 May 15.
Published in final edited form as: Life Sci. 2018 Mar 21;201:63–71. doi: 10.1016/j.lfs.2018.03.041

Figure 8. Reduction of type I collagen and αSMA but not PCNA in pBOO bladder by LY294002 treatment.

Figure 8

LY294002 (LY) treatment reduces the protein levels of type I collagen (A-B) and αSMA (A, C) in pBOO bladder when compared to those in vehicle-treated pBOO bladder (#, p<0.05). There are no significant difference in the levels of type I collagen (A-B) and αSMA (A, C) in LY-treated pBOO bladder when compared to LY-treated sham control. LY treatment does not reduce the protein (A, D) and mRNA (E) levels of PCNA in pBOO bladder when compared to those in vehicle-treated pBOO bladder. There is still a significant up-regulation of PCNA in LY-treated pBOO bladder when compared to LY-treated sham control (&, p<0.05). Vehicle treatment does not affect the up-regulation of type I collagen (A-B), αSMA (A, C) and PCNA (A, D-E) caused by pBOO when compared to vehicle-treated sham control (*, p<0.05).